Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com -- Royal Philips on Tuesday reported a 47% drop in second-quarter net income, citing the absence of a one-time insurance gain recorded in the prior year, while key operating metrics including margins and free cash flow improved.
Net income fell to €240 million from €452 million in the second quarter of 2024. Income from operations declined to €400 million from €816 million, reflecting the impact of a €538 million insurance gain booked last year related to the Philips Respironics recall.
Adjusted EBITA rose to €540 million from €495 million, with the adjusted EBITA margin increasing to 12.4% from 11.1%.
Group sales declined 3% to €4.34 billion but rose 1% on a comparable basis. Free cash flow improved to €230 million from a negative €64 million, while operating cash flow rose to €387 million from €89 million.
Comparable order intake rose 6%, following 9% growth in the second quarter of 2024, supported by new product launches and long-term contracts.
Segment performance was mixed. Personal Health grew 6% on a comparable basis to €862 million in sales, up from €834 million.
The segment’s adjusted EBITA margin fell to 15.2% from 16.9%, due to higher advertising and promotion expenses.
Connected Care sales declined to €1.27 billion from €1.33 billion, with the margin rising to 10.4% from 8.8%.
Diagnosis & Treatment reported €2.08 billion in sales, down from €2.17 billion, while its margin increased to 13.5% from 12.2%.
Geographically, comparable sales in mature markets were flat. Growth geographies rose 2%, despite lower sales in China.
North America and Western Europe posted 0% comparable sales growth. Total (EPA:TTEF) sales declined 4% in North America and 1% in Western Europe.
Philips recorded €86 million in charges, including €46 million in restructuring and acquisition-related costs, €34 million in field action running costs, €21 million tied to a consent decree, and a €23 million gain from a contract settlement.
The Dutch company maintained its full-year comparable sales growth outlook of 1% to 3% and raised its adjusted EBITA margin forecast to 11.3% to 11.8%, up from 10.8% to 11.3%.
The updated margin guidance reflects a revised estimated tariff impact of €150 million to €200 million, down from a prior range of €250 million to €300 million. Free cash flow is now projected between €0.2 billion and €0.4 billion for the year.
The outlook excludes effects from ongoing legal and regulatory matters involving Philips Respironics, including a U.S. Department of Justice investigation.
Philips paid a dividend of €0.85 per share for 2024 in the second quarter, with 41.4% paid in cash and the remainder in shares.